Marten Vos Email and Phone Number
australia
Marten Vos's Location
Auckland, Auckland, New Zealand, New Zealand
About Marten Vos
Leading technical and pharmaceutical R&D teams through transition and high-growth cycles. Established strategic vision for transfer of technology from R&D to manufacturing floor to solve difficult pharmaceutical API development, formulation, development, production, and regulatory compliance challenges. Built and restructured technical groups to maximize scientific excellence and practical output in global and domestic markets.More than 25 years of experience in the development of fine chemicals, nutraceuticals and pharmaceuticals to improve the health of humans and animals. Deep understanding of innovation and development from API to drug products, including generics, new chemical entities and radio-pharmaceuticals. Development expertise from early medicinal chemistry concepts (hit to lead) to commercialisation.Key skills: • New Product R&D• Cross-functional Leadership• Strategic Planning and Execution• Budget Planning and Management• CMC• R&D facility design and construction• Pharmaceutical Technology• Dosage Form / Chemical / Analytical Development• Clinical Supply Production / Distribution• Clinical Studies (Bioequivalence, Phase I & II)• GxP Compliance• FDA (pre-approval) audits• QMS (Veeva, Scilife)• Vendor Relations• Quality by Design (QbD)• Process Engineering• Drug Substance / API Development• Container Closure / Packaging Development• Pharmacokinetics• Toxicology• Drug Metabolism• Medicinal Chemistry• Synthetic Organic Chemistry• Nutraceuticals / Complementary Medicines• Fine / Specialty Chemicals
Marten Vos's Current Company Details
Medicines Development For Global Health
View
Senior R&D and Pharmaceutical Development Leader
australia
- Website:
- medicinesdevelopment.com
- Employees:
- 25
Marten Vos Work Experience Details
-
Associate Director CmcMedicines Development For Global Health Jan 2024 - PresentMelbourne, Victoria, AustraliaKey member of the Medicines Development for Global Health CMC operations team, responsible for the development and implementation of CMC strategies for Medicines Development for Global Health products, spanning early development through to product registration.
-
Independent ConsultantSelf-Employed Jan 2023 - PresentAuckland, New ZealandProviding CMC, Chemistry, Technical, Product and Process Development advice and expertise to Pharmaceutical (Human & Veterinary), Chemical, Nutraceutical, Dairy and Food Industries.
-
Director Of Research And DevelopmentHelius Therapeutics Sep 2021 - Dec 2021Auckland, New ZealandResponsible for all R&D functions in this startup company focused on cannabis based therapeutics.Key Accomplishments:◾ First regulatory approval and launch of a New Zealand made cannabidiol product under the NZ Medicinal Cannabis Regulations 2019.◾ Implemented a Stage-Gate process to manage and prioritise the R&D portfolio.◾ Proposed to separate R&D from GMP operations to increase flexibility and productivity.◾ Proposed to establish regulatory and clinical teams to support product registrations with clinically proven label claims. -
Senior Director Pharmaceutical Development ApacElanco Aug 2020 - Jul 2021Auckland, New ZealandContinuation of previous role with Bayer Animal Health upon completion of the sale to Elanco Animal Health. Responsible for all pharmaceutical development (CMC & Regulatory), product / technology transfers to manufacturing and lifecycle management activities of commercial product for the Asia Pacific region.Key Accomplishments:◾ Successful integration of the Bayer Animal Health APAC PD team into the new Elanco company structure.◾ Successful completion of the new APAC R&D laboratory and containment pilot plant on schedule and within budget despite the Covid-19 pandemic.◾ Multiple successful product transfers. ◾ Development of a novel controlled release anti-inflammatory product. -
Head Of Pharmaceutical Development ApacBayer Animal Health Mar 2020 - Aug 2020Auckland, New ZealandResponsible for all pharmaceutical development (CMC & Regulatory), product / technology transfers to manufacturing and lifecycle management activities of commercial product for the Asia Pacific region. Hired to manage the transition of the Bayer Animal Health APAC Pharmaceutical Development team into the Elanco company structure as part of the sale to Elanco.Key Accomplishments:◾ Restructured the Bayer Animal Health APAC PD team to accommodate for the new post acquisition Elanco company structure.◾ Streamlined development operations to increase flexibility and increase output of the team.◾ Successful relocation of the Bayer APAC R&D laboratory to the new Elanco APAC R&D facility under construction.◾ Achieved continuity of BAU for products under development while relocating R&D facilities and preparing for new company ownership. -
Pharmaceutical Development ManagerDouglas Pharmaceuticals Limited Apr 2018 - Mar 2020Auckland, New ZealandResponsible for all pharmaceutical development (CMC development, regulatory support and technology transfer into manufacturing) at the NZ and USA sites. Managed a team of 36 research scientists responsible for technical development of an R&D project portfolio with a NPV> 200MM USD. Promoted from my previous role as Formulation Development Manager this role was created to consolidate formulation development and 2 analytical development teams under single leadership.Key accomplishments:◾ Integrated formulation, analytical and method development teams into one pharmaceutical development team.◾ CMC development of multiple products resulting in 14 ANDA approvals to date.◾ CMC development of multiple products resulting in 2 EU product approvals to date.◾ Oversaw multiple drug repurposing developments resulting in positive top-line results from Phase 2 trials for one of the molecules.◾ Provide CMC support to major development partnership with mid-sized US Pharma company as well as several other US Pharma companies. -
Formulation Development ManagerDouglas Pharmaceuticals Limited Feb 2015 - Apr 2018Auckland, New ZealandResponsible for all formulation development at the NZ site. Managed a team of 10 formulation scientists responsible for dosage form and process development. Was asked by senior management to return to pharmaceutical R&D to take up the role of Formulation Development Manager in order to support the CSO and R&D director in building an R&D project portfolio with a NPV> 200MM USD.Key Accomplishments:◾ Restructured and expanded the formulation development team.◾ Promoted to Pharmaceutical Development Manager.◾ 2 ANDA approvals.◾ Developed product formulations resulting in 12 ANDA applications.◾ Started several 505(b)2 product formulation developments to diversify the company R&D pipeline into more novel high value product developments.◾ Hired talented young scientists to increase team capabilities.◾ Provided support to the regulatory function to obtain product approvals.
-
Technical Manager, Natural Health Laboratories LtdDouglas Pharmaceuticals Limited Sep 2011 - Feb 2015Auckland, New ZealandResponsible for all technical aspects and integration of the neutraceuticals business unit (Natural Health Laboratories Ltd) into the Douglas group in order to maintain regulatory compliance and provide technical support to sales, marketing and customers. Managed a team of 5 direct reports at head office in Auckland and a further 3 dotted line reports at the manufacturing facility in Fiji.Key Accomplishments:◾ Launch of the ‘Clinicians of NZ’ product range in Singapore pharmacies.◾ Regulatory approvals for 4 products for the Malaysian market.◾ Development of a selection of 25 Clinicians products suitable for ARTG listing with the Australian TGA. ◾ Implemented a quality framework more aligned with the pharma business in order to future proof nutraceutical manufacture and maintain compliance with regulatory changes proposed by the NZ authorities.◾ Introduced process validation to improve product quality and facilitate export.◾ Introduced stability programs to support shelf life claims and facilitate export.
-
Research OfficerDouglas Pharmaceuticals Limited Jul 2008 - Sep 2011Responsible for the technical aspects of new product development. Managed a small team of analytical and formulation scientists developing drug products and preparing CMC documentation to support regulatory submissions.Key Accomplishments:◾ First ANDA approval for Douglas by the US FDA.◾ EU approval for a line extension to a major Douglas export product.◾ First NDA approval for Douglas by the US FDA◾ First person in R&D to write a business case and present this to senior management as part of the implementation of a Stage-Gate process to manage new product developments.
-
R&D Chemist, Group LeaderSyncom Bv 1999 - 2007Groningen, NetherlandsResponsible for kilogram laboratory operations and scale up of synthetic organic chemistry routes for custom synthesis of complex novel molecules. Managed a team of four synthetic organic chemists (MSc / PhD) specialized in scale up from mg to kg quantities and redesign of synthetic routes to facilitate scale up of the synthesis of novel lead structures, pharmaceutical reference compounds and preclinical drug development. Reported to the CEO. Key Accomplishments:◾ Actively involved in design and construction of new 27,000 sq ft building including pilot plant facilties to double company footprint.◾ Increased pilot plant capabilities with acquisition of first 50 L multipurpose reactor.◾ Recruitment of new staff to accommodate company growth (15-30% per annum from 2000 to 2006).◾ Trained staff in process development and scale up operations. ◾ 60 completed projects.◾ 270 molecules synthesized. -
R&D ChemistIntersynth Bv 1997 - 1999Groningen, NetherlandsResponsible for synthesis, route scouting and scale up of fine chemicals up to kilogram scale. Supervised two research chemists and oversaw general laboratory operations and maintenance. Reported to the founder.Key Accomplishments:◾ Promoted (6 months after hire) to supervise staff and oversee laboratory operations. ◾ Trained staff in scale up operations. ◾ Obtained considerable expertise in applied synthetic organic chemistry.◾ Specialized in route design and process development for scale up.
-
RadiochemistUmcg 1993 - 1995Groningen, NetherlandsEmployed within the Positron Emission Tomography (PET) group of the department of Nuclear Medicine on a 2 year grant from the Dutch Digestive Foundation. The primary objective was to synthesize radioactively labelled molecules for imaging of tissue regeneration after liver transplants and automate the process the facilitate routine production.Key Accomplishments:◾ Developed and optimized of the synthesis of [11C]-labelled thymidine. ◾ Developed and constructed a PLC controlled system for synthesis of [11C]-labelled thymidine.◾ Developed and synthesized [18F]-labelled derivatives of thymidine as alternatives for [11C]-labelling and possible labelling of “antisense” nucleotides.◾ Research results presented during the Eleventh International Symposium on Radiopharmaceutical Chemistry (August 1995, Vancouver, Canada). -
Undergraduate Student ResearcherUmcg 1992 - 1993Groningen, NetherlandsResearch period within the Positron Emission Tomography (PET) group (supervisors Professor P.H. Elsinga Ph.D. and G.M. Visser Ph.D.) of the department of Nuclear Medicine. The primary objective was the synthesis and in vivo evaluation of radioactively labelled [18F]-fluorocarazolol a ligand for the visualisation of pulmonary beta-adrenergic receptors with Positron Emission Tomography (PET).Key Accomplishments:◾ Granted an Engineers Degree in chemistry◾ Developed an improved stereo selective synthesis of fluorocarazolol.◾ Synthesis and in vivo evaluation of radioactively labelled [18F]-fluorocarazolol. ◾ Research results presented during the Tenth International Symposium on Radiopharmaceutical Chemistry (October 1993, Kyoto, Japan).◾ PET imaging results of pulmonary beta-adrenoceptors presented during the 41st annual meeting of the Society of Nuclear Medicine (June 1994 Orlando, Fl, USA).◾ Full paper: Nucl. Med. Biol. 1996 23 159-167.
Marten Vos Education Details
-
Postgraduate Courses -
Engineer'S Degree -
Het Hogeland College
Frequently Asked Questions about Marten Vos
What company does Marten Vos work for?
Marten Vos works for Medicines Development For Global Health
What is Marten Vos's role at the current company?
Marten Vos's current role is Senior R&D and Pharmaceutical Development Leader.
What schools did Marten Vos attend?
Marten Vos attended University Of Groningen, Hanzehogeschool Groningen, Het Hogeland College.
Who are Marten Vos's colleagues?
Marten Vos's colleagues are Sarah Kilpatrick, Amanda Handley, Jane Fisher, Melinda Lowe, Molly Kennedy, Victoria Ryg-Cornejo, Priyanka Sathe.
Not the Marten Vos you were looking for?
-
-
marten vos
Afdelingshoofd / Projectleider Meet En Regeltechniek Bij De Groot Installatie GroepGreater Groningen Area -
Marten Vos
Groningen -
Free Chrome Extension
Find emails, phones & company data instantly
Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Aero Online
Your AI prospecting assistant
Select data to include:
Total price:
$0.00
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial